Abstract
The decision to move forward with three clinical trials of IL-1 blockade for treatment of acute Kawasaki disease is a case study in translational science. These trials were born on the one hand from transcriptome studies of host response during the acute disease coupled with animal model investigations of key immune signaling pathways and, on the other hand, out of clinical desperation to intervene in patients with severe inflammation in the setting of acute Kawasaki disease. The convergence of laboratory science and clinical observations led to the clinical trials described here and serves as a model for how such observations can be translated into new therapies.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acute Disease
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use*
-
Interleukin 1 Receptor Antagonist Protein / therapeutic use
-
Interleukin-1 / antagonists & inhibitors*
-
Interleukin-1 / metabolism
-
Mucocutaneous Lymph Node Syndrome / drug therapy*
-
Mucocutaneous Lymph Node Syndrome / etiology
-
Translational Research, Biomedical
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunoglobulins, Intravenous
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1
-
Tumor Necrosis Factor-alpha
-
canakinumab